Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Green light for development deal
November 2018
SHARING OPTIONS:

MECHELEN, Belgium & PLANEGG/MUNICH, Germany—Galapagos NV and MorphoSys AG recently announced that, with the expiration of the waiting period under the Hart-Scott-Rodino Act, they had attained U.S. antitrust clearance for their license agreement with Novartis Pharma AG. The deal to develop and commercialize MOR106 was struck on July 19, 2018, and became effective on September 10. In conjunction with this, the €95 million upfront payment by Novartis is now payable. Per the agreement, the companies will broaden the current development plan for MOR106 in atopic dermatitis, and Novartis will hold all commercialization rights for any products resulting from the deal. In addition, all Novartis will be responsible for all future research, development, manufacturing and commercialization costs for MOR106. MorphoSys and Galapagos will conduct additional trials to support the compound’s advancement in atopic dermatitis.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.